Neuvasq

Gosselies, Belgium, May 05, 2026 (GLOBE NEWSWIRE) --

Gpr124 represents a promising novel target for improving the integrity and function of the blood-retina barrier (BRB) with the goal of slowing, halting, preventing or even reversing vision loss Neuvasq's most advanced programs are NVQ401, a first-in-class

Neuvasq Biotechnologies

EQS-News: Neuvasq Biotechnologies / Key word(s): Conference/Research Update Neuvasq ARVO data 05.05.2026 / 21:15 CET/CEST The issuer is solely responsible for the content

Neuvasq was pleased to have been selected for an oral presentation at the annual European Brain Barriers Meeting that took place in Bern on September 8-10. Sylvaine Guérit, Head of Preclinical Research, had the opportunity to present new efficacy data for

Neuvasq had the opportunity to share new preclinical data at Euretina, the most important European ophthalmology congress, which took place on September 4-7 in Paris. In its poster, Neuvasq disclosed for the first time additional preclinical data confirmi

Neuvasq Biotechnologies, a privately held biotech company based in Gosselies (Belgium) dedicated to advancing pioneering therapies to restore CNS blood barriers in patients withophthalmologic and neurologic conditions, is announcing the appointment of Den

Neuvasq was pleased to participate in the ARVO 2025 Annual Meeting, held from May 4-8 in Salt Lake City, where the company presented recent progress in its blood-retina barrier (BRB) research. During a poster session on Monday, May 8, Neuvasq's Chief Scie

At the Cold Spring Harbor Laboratory Conference on Blood-Brain Barriers, Dr. Sylvaine Guerit (Head of Preclinical Research) will present a poster detailing in vitro and in vivo results supporting Neuvasq's Wnt surrogate antibody program in vascular retino